The KRAS-variant and its impact on normal breast epithelial cell biology

Jung, Song-Yi; Malhotra, Poonam; Nguyen, Kiana C; Salzman, David W.; Qi, Yue; King, Joshua; Vlashi, Erina; Ann, David K.; Weidhaas, Joanne B.

doi:10.1038/s41418-019-0320-y

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its occurrence is associated with increased cancer risk and is predictive of drug response and elevated TGF-β and immunosuppression in cancer patients. KRAS-variant normal breast epithelial cells exhibit a mesenchymal phenotype, which appears to be due to numerous molecular changes and pathway alterations, including elevated aTGF-β signaling, resulting in ZEB and SNAIL up-regulation [ 92 ].…”

Section: Autocrine Tgf-β In the Regulation Of Specific Proteinsmentioning

confidence: 99%

Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis

Ungefroren

2021

IJMS

View full text Add to dashboard Cite

Autocrine signaling is defined as the production and secretion of an extracellular mediator by a cell followed by the binding of that mediator to receptors on the same cell to initiate signaling. Autocrine stimulation often operates in autocrine loops, a type of interaction, in which a cell produces a mediator, for which it has receptors, that upon activation promotes expression of the same mediator, allowing the cell to repeatedly autostimulate itself (positive feedback) or balance its expression via regulation of a second factor that provides negative feedback. Autocrine signaling loops with positive or negative feedback are an important feature in cancer, where they enable context-dependent cell signaling in the regulation of growth, survival, and cell motility. A growth factor that is intimately involved in tumor development and progression and often produced by the cancer cells in an autocrine manner is transforming growth factor-β (TGF-β). This review surveys the many observations of autocrine TGF-β signaling in tumor biology, including data from cell culture and animal models as well as from patients. We also provide the reader with a critical discussion on the various experimental approaches employed to identify and prove the involvement of autocrine TGF-β in a given cellular response.

show abstract

Section: Autocrine Tgf-β In the Regulation Of Specific Proteinsmentioning

confidence: 99%

Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis

Ungefroren

2021

IJMS

View full text Add to dashboard Cite

show abstract

Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer

Poor

Keivan

Ramazii

et al. 2021

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer and the prevalent type of malignancy among women. Multiple risk factors, including genetic changes, biological age, dense breast tissue, and obesity are associated with BC. The mitogen-activated protein kinases (MAPK) signaling pathway has a pivotal role in regulating biological functions such as cell proliferation, differentiation, apoptosis, and survival. It has become evident that the MAPK pathway is associated with tumorigenesis and may promote breast cancer development. The MAPK/RAS/RAF cascade is closely associated with breast cancer. RAS signaling can enhance BC cell growth and progression. B-Raf is an important kinase and a potent RAF isoform involved in breast tumor initiation and differentiation. Depending on the reasons for cancer, there are different strategies for treatment of women with BC. Till now, several FDA-approved treatments have been investigated that inhibit the MAPK pathway and reduce metastatic progression in breast cancer. The most common breast cancer drugs that regulate or inhibit the MAPK pathway may include Farnesyltransferase inhibitors (FTIs), Sorafenib, Vemurafenib, PLX8394, Dabrafenib, Ulixertinib, Simvastatin, Alisertib, and Teriflunomide. In this review, we will discuss the roles of the MAPK/RAS/RAF/MEK/ERK pathway in BC and summarize the FDA-approved prescription drugs that target the MAPK signaling pathway in women with BC.

show abstract

Comprehensive bioinformatics analysis of CYB561 expression in breast cancer: Link between prognosis and immune infiltration

Yang¹,

WU²,

XIONG³

et al. 2023

Biocell

View full text Add to dashboard Cite

The KRAS-variant and its impact on normal breast epithelial cell biology

Cited by 3 publications

References 32 publications

Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis

Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis

Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer

Comprehensive bioinformatics analysis of CYB561 expression in breast cancer: Link between prognosis and immune infiltration

Contact Info

Product

Resources

About